FDA Seeks New Generics Chief As Choe Moves On
Search Begins For Permanent Replacement As Interim Acting Director Named
Executive Summary
The US Food and Drug Administration has begun searching for a new director for its Office of Generic Drugs, after announcing that Sally Choe will leave the agency in early October.
You may also be interested in...
2022 Hires Reflect Global Challenges And Opportunities
Executive changes in 2022 reveal how the industry is adjusting to a volatile post-COVID environment.
US FDA Wants More Generic-Specific Experience In Next OGD Director
Vacancy notice includes preferences for candidates with experience formulating generic drug policy and strategy, as well as in overall drug development, which is intended to make the search more efficient.
Generics Bulletin Editor’s Picks For Q3 2022
Looking back over the third quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from July to September that include changes in ownership on the horizon for major industry players, executive reshuffles at the top of leading companies and regulators, Generics Bulletin’s annual Top 50 and the announcement of our annual awards shortlist.